FIELD: medicine, pharmaceutics.
SUBSTANCE: composition for medical use contains a solid or semisolid matrix, at least one active ingredient uniformly dispersed therein. The matrix contains at least one pharmaceutically acceptable matrix-forming agent and compound 1,3-bis(lactamyl)butane, especially 1,3-bis(pyrrolidone-1-yl)butane. The active component has water-solubility less than 1 g/100 ml at 25°C. The active ingredient is preferentially dispersed in a matrix as a solid solution. The matrix-forming agent is chosen from a group of alcohol sugars, alcohol sugar derivatives, pharmaceutically acceptable polymers and their mixtures. The composition is used for preparing the pharmaceutical dosage forms for oral administration of the active ingredients.
EFFECT: composition provides higher bioavailability of poorly water-soluble active ingredient due to its presence in the composition in a non-crystalline state.
19 cl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
PHARMACEUTICAL DOSED FORM, CONTAINING POLYMER CARRIER COMPOSITION | 2009 |
|
RU2519679C9 |
PHARMACEUTICALLY ACCEPTABLE SOLUBILISING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING IT | 2007 |
|
RU2469708C2 |
IMPROVED WAY OF PREPARATION OF THE ACTIVE COMPONENT FIRM DISPERSION | 2007 |
|
RU2442568C2 |
DEVICE FOR PREPARING SOLID DISPERSION OF ACTIVE INGREDIENT | 2007 |
|
RU2448688C2 |
COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE | 2003 |
|
RU2356549C2 |
PERORAL SOLID DOSAGE FORM WITH MYCOPHENOLIC ACID OR ITS SALT FOR USE AS AN IMMUNODEPRESSANT FOR TREATMENT OR PREVENTION OF ORGAN OR TISSUE TRANSPLANT REJECTION AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2670447C2 |
COMPOSITION CONTAINING FENOFIBRIC ACID OR PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND CAPSULE CONTAINING COMPOSITION | 2008 |
|
RU2500398C2 |
HEPARIN-BASE FORMULATION | 2001 |
|
RU2278658C2 |
EXTRUDATE WITH SODIUM MYCOPHENOLATE TO PRODUCE PERORAL SOLID DOSAGE FORM | 2018 |
|
RU2723255C2 |
Authors
Dates
2011-07-20—Published
2006-06-22—Filed